HIV Scientific Papers
The impact of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on body image and health-related quality of life in HIV-infected patients with abdominal fat accumulation.
2007
Turner RR, Falutz J, Testa MA, et al.
Poster #P22 presented at: the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV: July 19-21, 2007; Sydney, Australia.
Effects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation: a multicenter, double-blind placebo-controlled trial with 412 randomized patients [abstract].
2007
Falutz J, Allas S, Blot K, et al.
#45LB. The 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California, USA.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
2007
N Engl J Med.
Falutz J, Allas S, Blot K, et al.
357(23):2359-2370.
TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks [abstract].
2006
Norris D, Morales J, Godofsky E, et al.
XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
2005
AIDS.
Falutz J, Allas S, Kotler D, et al.
19(12):1279-1287.